Gene Therapy for Children With CLN3 Batten Disease

NCT03770572 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

CLN3
Batten Disease

Interventions

GENETIC: Low dose CLN-301
GENETIC: High dose CLN-301

Sponsor

Alcyone Therapeutics, Inc